Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $6,207,856.20 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) major shareholder Vivek Ramaswamy sold 547,430 shares of the business’s stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $11.34, for a total value of $6,207,856.20. Following the transaction, the insider now directly owns 38,627,181 shares in the company, valued at $438,032,232.54. This trade represents a 1.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Vivek Ramaswamy also recently made the following trade(s):

• On Friday, June 6th, Vivek Ramaswamy sold 200,800 shares of Roivant Sciences stock. The stock was sold at an average price of $11.19, for a total value of $2,246,952.00.
• On Tuesday, May 6th, Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock. The stock was sold at an average price of $11.47, for a total value of $3,142,309.73.

Roivant Sciences Stock Up 0.3%

Shares of ROIV stock opened at $11.23 on Monday. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $13.06. The business has a fifty day simple moving average of $10.64 and a 200 day simple moving average of $11.01. The company has a market cap of $8.01 billion, a P/E ratio of -74.86 and a beta of 1.16.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Thursday, May 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.15). The firm had revenue of $7.57 million during the quarter, compared to analyst estimates of $62.17 million. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. During the same period in the previous year, the company earned ($0.23) EPS. As a group, equities research analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a report on Wednesday, May 28th.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently made changes to their positions in ROIV. FMR LLC grew its stake in Roivant Sciences by 0.3% during the fourth quarter. FMR LLC now owns 49,301,583 shares of the company’s stock worth $583,238,000 after purchasing an additional 156,527 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock valued at $521,553,000 after purchasing an additional 2,404,232 shares in the last quarter. Patient Square Capital LP lifted its holdings in shares of Roivant Sciences by 2.1% in the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company’s stock valued at $147,638,000 after purchasing an additional 251,535 shares in the last quarter. Two Seas Capital LP lifted its holdings in shares of Roivant Sciences by 4.6% in the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company’s stock valued at $120,285,000 after purchasing an additional 442,914 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Roivant Sciences by 3.8% in the first quarter. Invesco Ltd. now owns 9,880,526 shares of the company’s stock valued at $99,695,000 after purchasing an additional 365,468 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.